Back
  1. Home
  2. Profile of Aurélie Poncin (ULiège)
Profil

Poncin Aurélie

Département des sciences cliniques

See author's contact details
Main Referenced Co-authors
Jerusalem, Guy  (10)
Freres, Pierre  (9)
Bours, Vincent  (8)
Josse, Claire  (7)
Onesti, Concetta Elisa  (5)
Main Referenced Keywords
oncology (4); Chemotherapy (3); Humans (3); Immunotherapy (3); breast cancer (2);
Main Referenced Disciplines
Oncology (12)
Cardiovascular & respiratory systems (1)
Immunology & infectious disease (1)

Publications (total 14)

The most downloaded
2886 downloads
Lecocq, M., Poncin, A., & Sautois, B. (2021). Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou. Revue Médicale de Liège, 76 (5-6), 398-402. https://hdl.handle.net/2268/261307

The most cited

68 citations (OpenAlex)

Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4 https://hdl.handle.net/2268/225226

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571
Peer Reviewed verified by ORBi

Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087
Peer Reviewed verified by ORBi

Uyisenga, J. P.* , Debit, A.* , Poulet, C., Frères, P., Poncin, A., Thiry, J., Mutesa, L., Jerusalem, G., Bours, V.* , & JOSSE, C.*. (03 June 2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports, 11 (1), 11698. doi:10.1038/s41598-021-91278-0
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Freres, P., Poncin, A., & Lecocq, M. (May 2021). Les manifestations indésirables liées à l’immunothérapie. Revue Médicale de Liège, 76 (5-6), 403 - 407.
Editorial Reviewed verified by ORBi

Lecocq, M., Poncin, A., & Sautois, B. (2021). Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou. Revue Médicale de Liège, 76 (5-6), 398-402.
Peer reviewed

LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain.

PONCIN, A., & Jerusalem, G. (2020). Evolution des thérapies anti-cancéreuses systémiques. Revue Médicale de Liège, 75 (5-6), 466-472.
Peer reviewed

ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120
Peer Reviewed verified by ORBi

ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment [Paper presentation]. GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology.

Herfs, M., RONCARATI, P., KOOPMANSCH, B., Peulen, O., Bruyère, D., Lebeau, A., Hendrick, E., Hubert, P., PONCIN, A., Penny, W., Piazzon, N., Monnien, F., Guenat, D., Mougin, C., Prétet, J.-L., Vuitton, L., SEGERS, K., LAMBERT, F., BOURS, V., ... Delvenne, P. (2018). A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine. British Journal of Cancer, 118(10), 1302-1312. doi:10.1038/s41416-018-0049-2
Peer Reviewed verified by ORBi

Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4
Peer Reviewed verified by ORBi

Narinx, J., Poncin, A., HUYNEN, P., Moutschen, M., & GIOT, J.-B. (2017). Atteinte hépato-splénique et bartonellose systémique chez une patiente immunocompétente. Revue Médicale de Liège, 72 (7-8), 331-335.
Peer reviewed

FRERES, P., PONCIN, A., MOONEN, M., Josse, C., Oury, C., BOURS, V., LANCELLOTTI, P., & JERUSALEM, G. (2016). La cardiotoxicité des traitements anti-cancéreux. Revue Médicale de Liège, 71 (9), 382-387.
Peer reviewed

JERUSALEM, G., COLLIGNON, J., Josse, C., SCHROEDER, H., RORIVE, A., FRERES, P., LAMBERT, F., KOOPMANSCH, B., PONCIN, A., & BOURS, V. (2015). Cancer du sein : de la thérapie ciblée à la médecine personnalisée. Revue Médicale de Liège, 70 (5-6), 269-276.
Peer reviewed

Contact ORBi